Eagle Pharmaceuticals (EGRX): Analyst Day Takeaway - RBC
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
RBC Capital analyst, Randall Stanicky, reiterated his Outperform rating on shares of Eagle Pharmaceuticals (NASDAQ: EGRX) after the analyst day and is confident in the BENDEKA base and encouraged on the potential for value creation.
Pipeline was the focus at the analyst meeting though there is still a strategic build-out taking place that should enhance value over time. No change to the Outperform rating or $93 PT.
Shares of Eagle Pharmaceuticals closed at $79.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: BMO Capital Upgrades Williams Partners LP (WPZ) to Outperform
- Clovis Oncology (CLVS) PT Raised to $86 as Stifel Adopts Takeout Valuation
- Jefferies Upgrades Williams Companies (WMB) to Buy
Create E-mail Alert Related CategoriesAnalyst Comments
Related EntitiesRBC Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!